Eupraxia Pharmaceuticals is trading 15.68% up at $8.04 in pre-market on October 20, 2026, with no confirmed new company announcement directly explaining the move.
- The RESOLVE trial recently reached its 120-patient enrollment target, and presentations were scheduled at UEG Week; available reports do not establish either as the cause.
- Supplied market context is mixed to weaker and does not clearly account for the rise.
- Supplied price history shows a $6.95 previous close; no reliable pre-market volume information was provided.